Skip to main content
. 2018 Oct 12;19(10):3127. doi: 10.3390/ijms19103127

Figure 1.

Figure 1

Emodin sensitizes hepatocellular carcinoma (HCC) cells to the anti-cancer effect of sorafenib. (A) Cell viability analysis after emodin, sorafenib, or the combination treatment of both drugs in five HCC cell lines. The cells were incubated with emodin (20 μM), sorafenib (2 μM), or the combination (20 μM emodin and 2 μM sorafenib) for 24, 48, or 72 h, as indicated. The values represent the mean ± SEM of three independent experiments performed in triplicate; * p < 0.05, ** p < 0.01, and *** p < 0.001. (B) Images of crystal violet staining. (C) The cell viability after different concentrations of sorafenib (0.5, 1, 2, 5, and 10 μM) with 20 μM emodin in Hep3B, HepG2, and Huh7 cells. The values represent the mean ± SEM of three independent experiments performed in triplicate; * p < 0.05 and ** p < 0.01.